Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Longboard Pharmaceuticals, Inc.

Get SEC filing alerts via email and in your feed for Longboard Pharmaceuticals, Inc.

LBPH

Longboard Pharmaceuticals, Inc.

About Longboard Pharmaceuticals, Inc.

Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for neurological diseases. Its pipeline includes small molecule candidates like bexicaserin, a selective 5-HT2C receptor superagonist for epileptic encephalopathies, and LP659, a CNS-penetrant S1P receptor modulator for neuroinflammatory conditions. The company leverages proprietary GPCR research to create innovative, highly selective treatments addressing unmet medical needs in neurology.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Longboard Pharmaceuticals, Inc.

1
1
Longboard Pharmaceuticals, Inc. Longboard Pharmaceuticals Reports Significant Financial Growth, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments